tbuckley/cabot-search huggingface dataset:
HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy
Authors: Kanika Kanchan, Stepan Grinek, Henry T. Bahnson, Ingo Ruczinski, Gautam Shankar, David Larson, George Du Toit, Kathleen C. Barnes, Hugh A. Sampson, Mayte Suarez-Farinas, Gideon Lack, Gerald T. Nepom, Karen Cerosaletti, Rasika A. Mathias
Journal: Journal of Clinical Investigation (2022)

We investigated the interplay between genetics and oral peanut protein exposure in the determination of the immunological response to peanut using the targeted intervention in the LEAP clinical trial. We identified an association between peanut-specific IgG4 and HLA-DQA1*01:02 that was only observed in the presence of sustained oral peanut protein exposure. The association between IgG4 and HLA-DQA1*01:02 was driven by IgG4 specific for the Ara h 2 component. Once peanut consumption ceased, the association between IgG4-specific Ara h 2 and HLA-DQA1*01:02 was attenuated. The association was validated by observing expanded IgG4-specific epitopes in people who carried HLA-DQA1*01:02. Notably, we confirmed the previously reported associations with HLA-DQA1*01:02 and peanut allergy risk in the absence of oral peanut protein exposure. Interaction between HLA and presence or absence of exposure to peanut in an allergen- and epitope-specific manner implicates a mechanism of antigen recognition that is fundamental to driving immune responses related to allergy risk or protection.
Prognostic significance of exosomal programmed death-ligand 1 in advanced gastric cancer patients treated with first-line chemotherapy.
Authors: Kabsoo Shin, Joori Kim, Juyeon Park, Ok Ran Kim, Nahyeon Kang, In-Ho Kim
Journal: Journal of Clinical Oncology (2022)

Retraction The abstract by Shin et al entitled, “Prognostic significance of exosomal programmed death-ligand 1 in advanced gastric cancer patients treated with first-line chemotherapy,” ( Journal of Clinical Oncology 40, no. 4, suppl 665) published on February 1, 2022, has been retracted due to statistical errors that significantly changed the results and conclusion of the abstract. This abstract was retracted on November 4, 2022. 665 Background: Recent studies have found that exosomal PD-L1 could be associated with prognosis in several malignancies by its potential immunosuppressive role. Prognostic role of exosomal PD-L1 in advanced gastric cancer patients treated with systemic chemotherapy has not been well explored. The aim of the present study was to explore prognostic and predictive significance of exosomal PD-L1 in advanced gastric cancer patients. Methods: We prospectively collected plasma samples of patients with advanced gastric cancer receiving first-line chemotherapy at pre and post treatment. Combined ultracentrifugation with polymer-based precipitation was applied to isolate exosome and enzyme-linked immunosorbent assay(ELISA) was applied to measure exosomal PD-L1. The correlation between exosomal PD-L1 and circulating immune cells in the plasma was evaluated. Patients were divided into two groups according to pretreatment exosomal PD-L1 level. Survival analysis was performed using Kaplan-Meier method and multivariate analyses based on Cox-proportional hazards regression model. Results: A total of 99 patients were enrolled in the study, and serum samples collected at pre-treatment and post-treatment were pooled. Median value of the pre-treatment exosomal PD-L1 was 0.42 pg/ml (range 0.01 ̃3.75). Patients with pre-treatment exoPD-L1 &lt; 0.42 pg/mL (exoPD-L1 low ) showed significantly better overall survival than those with exoPD-L1 ≥ 0.42 pg/mL(exoPD-L1 high ) (p = 0.033). Progression-free survival was not different between the groups (p = 0.754). exoPD-L1 low group showed significantly higher percentages of CD8+T cells than exoPD-L1 high group. (p = 0.024). In multivariate analysis, pretreatment exosomal PD-L1, poorly differentiated tumors and No. of metastatic sites(≥2) were independent prognostic factors for overall survival. Conclusions: In summary, the level of pre-treatment exosomal PD-L1 could be used as a prognostic marker for patients with advanced gastric cancer receiving systemic chemotherapy.
Some Unusual Hurdles En Route to Fitness
Authors: Virginia S. Cowart
Journal: JAMA (1990)

AS THE NATION pursues physical fitness, members of the American College of Sports Medicine are hearing about such things as allergy to exercise, gold standard failure, and too much of a potentially good thing. These cases of "conditioning come a cropper" were outlined at the organization's annual meeting in Salt Lake City, Utah. In the first report, a 30-year-old woman, who had ridden an exercise bicycle regularly for several years, had a 2-week history of breaking out in a rash during exercise, and one episode of light-headedness. She was seen at the Parkside Sports Medicine Center of Lutheran General Hospital, Park Ridge, Ill. William Briner, MD, associate director of the center, says the woman's physical examination and blood pressure were unremarkable. Briner arranged for her to pedal a bicycle ergometer, and after 6 minutes the rash appeared. Four minutes later, her blood pressure dropped to 100/50 mm Hg. Briner's diagnosis
Treatment patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population.
Authors: Adriana Valderrama, Mukul Singhal, Liya Wang, Bal Nepal, Shital Kamble, Michael Grabner, Usha Malhotra, Milind M. Javle
Journal: Journal of Clinical Oncology (2022)

398 Background: The American Cancer Society estimates 11,980 new cases of biliary tract cancers (BTCs), including gall bladder and nearby large bile ducts, to occur in the US in 2021. BTCs are characterized by poor prognosis and limited treatment choices. Gemcitabine (GEM) plus platinum chemotherapy is the standard of care. However, there are limited data regarding real-world treatment patterns and clinical outcomes for BTCs patients receiving systemic treatments (ST). Methods: A retrospective cohort study of BTCs patients who received first line (1L) ST, using US private payer Cancer Care Quality Program (CCQP) data and administrative claims from the HealthCore Integrated Research Database (HIRD) between 07/01/2014 - 03/31/2021, was performed. Index date was defined as first claim of ST within 60 days of documented 1L therapy in the CCQP from 01/01/2015 - 09/30/2020. Adult BTCs patients with ≥6 months pre-index enrollment were included. Patients with ampullary cancer, brain/ CNS metastases, other primary cancer before BTCs diagnosis were excluded. Treatment patterns and clinical outcomes were examined. Results: A total of 413 patients [Stage IV (n=315), III (n=44), II/I (n=54)] were identified. The mean (SD) age was 61 (10) years, 55% were female, and there were 67% intrahepatic, 22% gall bladder, and 11% extrahepatic BTCs. There were 150 (36%), 203 (49%), 27 (7%) patients with baseline ECOG scores of 0, 1, 2+, respectively. At pre-index, frequently observed conditions included non-alcoholic liver diseases (75%), hypertension (65%), dyslipidemia (48%), mental health conditions (47%), gallstones (41%), gastrointestinal disorders (39%), and obesity (32%). GEM was commonly used as monotherapy (6%) or in combinations (85%): GEM + Cisplatin (64%), GEM + Oxaliplatin (6%), GEM + Capecitabine (5%), GEM + others (10%). Median overall survival was 11.5 months. The table summarizes clinical outcomes by stage. Conclusions: Most patients with BTCs received 1L GEM-based therapies, experienced poor survival and had high hospitalization rates. These data indicate need for future innovative approaches for management of BTC.[Table: see text]
Outlines of Obstetrics; a Syllabus of Lectures Delivered at the Long Island College Hospital.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>QuickStats:</i> Percentage* of Women Aged 22–44 Years Who Have Ever Cohabited with an Opposite-Sex Partner,† by Education§ — National Survey of Family Growth, United States, 2006–2010 and 2015–2019
Authors: Colleen Nugent
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Estimates are based on interviews of the U.S. household population for sample adults aged 22-44 years; 95% confidence intervals indicated with error bars.† Ever cohabited with an opposite-sex partner refers to whether respondent ever lived with an opposite-sex partner before or outside of marriage in their lifetime.§ Age and education of respondent are measured at time of interview.Among women aged 22-44 years, during 2015-2019, 67.3% had ever cohabited with an opposite-sex partner compared with 62.5% during 2006-2010.Among women with a high school diploma, GED, or less education, the percentages of those who had ever cohabited with an opposite-sex partner were similar (72.6%) across the two periods; the percentage of women with some college or higher education who had ever cohabited was higher for 2015-2019 (64.8%) than for 2006-2010 (56.0%).In both periods, women with a high school diploma, GED, or less education were more likely to have ever cohabited with an opposite-sex partner than were women with some college or higher education.
JAMA 75 YEARS AGO
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Medical Society
Authors: Edwin Bennett Astwood
Journal: New England Journal of Medicine (1976)

Edwin Bennett Astwood was born and raised in Bermuda, where as a boy he studied the stars through homemade telescopes and lived close to the sea. In 1972, he returned to Bermuda to practice medicine. He died on February 17, 1976, of cancer at the age of 66.Ted Astwood received an M.D. degree at McGill University in 1934 and a Ph.D. in biology from Harvard University in 1939. After a year as an associate in obstetrics at Johns Hopkins University, he returned in 1940 to Harvard, where for the next five years he had a combined appointment in the . . .
The Public Service.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: I Attili, A Passaro, F De Marinis, J Remon, L Hendriks, P Bironzo, B Özdemir, S Oertelt-Prigione, A Adjei, S Borchmann, J Haanen, A Letsch, O Mir, A Quaas, R Verhoeven, A Wagner, S Popat, P Baas, C Faivre-Finn, N Girard, A Nicholson, A Nowak, I Opitz, A Scherpereel, M Reck, G Middleton, H Robbins, F Andre, C Swanton, C Corti, G Antonarelli, F Scotté, J Spano, J Barrière, J Michot, F André, G Curigliano
Journal: Annals of Oncology (2022)

Thoracic tumorsFirst-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system
Authors: Sujeetha A. Rajakumar, Ildiko Grandal, Mark D. Minden, Johann K. Hitzler, Cynthia J. Guidos, Jayne S. Danska
Journal: Cell Reports Medicine (2021)

<h2>Summary</h2> Acute lymphoblastic leukemia (ALL) dissemination to the central nervous system (CNS) is a challenging clinical problem whose underlying mechanisms are poorly understood. Here, we show that primary human ALL samples injected into the femora of immunodeficient mice migrate to the skull and vertebral bone marrow and provoke bone lesions that enable passage into the subarachnoid space. Treatment of leukemia xenografted mice with a biologic antagonist of receptor activator of nuclear factor κB ligand (RANKL) blocks this entry route. In addition to erosion of cranial and vertebral bone, samples from individuals with B-ALL also penetrate the blood-cerebrospinal fluid barrier of recipient mice. Co-administration of C-X-C chemokine receptor 4 (CXCR4) and RANKL antagonists attenuate both identified routes of entry. Our findings suggest that targeted RANKL and CXCR4 pathway inhibitors could attenuate routes of leukemia blast CNS invasion and provide benefit for B-ALL-affected individuals.
Abstract 321: Protein Tyrosine Phosphatase 1B: a Novel Regulator of Proliferation and Apoptosis in the Development of Pulmonary Arterial Hypertension
Authors: Shayan Moazeni, Gregoire Ruffenach, Shervin Sarji, Christine Cunningham, Mylene Vaillancourt, Soban Umar, Mansoureh Eghbali
Journal: Circulation Research (2017)

Background: Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling that leads to an increase in pulmonary arterial pressure resulting in right ventricle failure and death. PAH is driven by pulmonary artery smooth muscle cell (PASMC) proliferation and resistance to apoptosis. Protein Tyrosine Phosphatase 1B (PTP1B), a negative regulator for platelet-derived growth factor (PDGF) and BCL-2, has recently been implicated in PAH in humans. While PDGF and BCL-2 are increased in PAH patients, the pathway for regulating BCL-2 and PDGF is poorly understood. We aim to investigate if PTP1B has a role in proliferation and resistance to apoptosis in PAH in human PACMCs and in the Sugen/Hypoxia/Normoxia (Su/Hx/Nx) PH rat model. Method: Adult male Sprague-Dawley rats were treated with single intraperitoneal dose of SU5416 (20 mg/kg) and kept in Hx for 3 weeks followed by Nx for 2 weeks. Saline treated rats kept in Nx for 5 weeks served as control (n=4/group). RV catheterization was performed terminally for recording RV systolic pressure (RVSP). RV, LV, and interventricular septum (IVS) were isolated for Fulton index (FI, RV/IVS+LV). We analyzed gene expression in lungs via qPCR. Healthy hPASMCs were incubated with a PTP1B inhibitor (Ethyl-3,4-dephostatin) at IC50=0.58ug/ml for 24hrs under Nx conditions and cells were stained with Ki67 to assess proliferation. Results: Su/Hx/Nx rats had severe PH evidenced by a significantly elevated RVSP compared to control (88.97+/- 13.67 vs 28.47+/- 2.22 mmHg, p&lt;0.05). PH rats also showed severely reduced RV function and increased RV hypertrophy (FI= 0.7+/- 0.063 vs 0.274 +/-0.01, p&lt;0.05). PH lungs exhibited severe pulmonary vascular remodeling with excessive growth of the PASMCs. PTP1B was significantly decreased in PH lungs compared to controls (0.158+/-0.0647 vs 1+/-0.06, P&lt;0.05). BCL-2 expression was significantly increased in PAH compared to control (2.01+/-0.162 vs 1 +/-0.1, P&lt;0.01). Inhibition of PTP1B in cultured hPASMCs increased proliferation by ~2 fold as assessed by Ki67 positive cells (n=3). Conclusion: Severe angioproliferative PH in rats is associated with a downregulation of PTP1B and increased expression of BCL-2 and PASMC proliferation.
Start as we mean to go on
Authors: None The Lancet Microbe
Journal: The Lancet Microbe (2020)

Welcome to the first issue of The Lancet Microbe, an open access journal for which we have ambitious plans. Our aim is to publish research that sets this journal apart from others in the clinical microbiology sphere, by catering to work exploring microbes and infectious agents at all scales. We will publish research ranging from the nature of the pathogen (eg, antimicrobial resistance genes or plasmids, virulence factors), to the microbiome, to pathology (including immunology), and to population-level effects (eg, outbreaks, epidemiology).
Deaths
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1961)

before the tube is withdrawn it is used to distribute 1-3 pints (0.6-1.7 litres) of 15% formaldehyde solution throughout the trunk cavities.The skin wound is closed by a purse- string suture.The body is then arranged in the required posture and examined after a few hours for adequacy of fixation as judged by the firmness of the tissues.Areas which still feel soft have not been reached by the embalming fluid and must be injected locally with 2% formaldehyde solution from a 20-ml.syringe fitted with an intramuscular needle.
Quick Uptakes...
Authors: Rebecca Voelker
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy Sherif N. Nagueh, Steve R. Ommen, Nasser M. Lakkis, Rick A. Nishimura, Donna Killip, William A. Zoghbi, Hartzell V. Schaf, Gordon K. Danielson, Miguel A. Qui�ones, A J. Tajik, William H. Spencer, III. Baylor College of Medicine, Houston, TX, Mayo Clinic, Rochester, MN
Journal: Journal of the American College of Cardiology (2001)
Characterization of discontinuation and nonpublication of phase <scp>III</scp> randomized clinical trials of psoriasis
Authors: Megan Lam, Caitlin Monaghan, An‐Wen Chan, Aaron M. Drucker
Journal: British Journal of Dermatology (2022)

Journal Article Characterization of discontinuation and nonpublication of phase III randomized clinical trials of psoriasis Get access Megan Lam, Megan Lam Michael G. DeGroote School of Medicine, Faculty of Medicine McMaster University Hamilton ON Canada https://orcid.org/0000-0001-5819-7684 Search for other works by this author on: Oxford Academic Google Scholar Caitlin Monaghan, Caitlin Monaghan Temerty Faculty of Medicine University of Toronto Toronto ON Canada https://orcid.org/0000-0001-7375-8013 Search for other works by this author on: Oxford Academic Google Scholar An‐Wen Chan, An‐Wen Chan Women’s College Research Institute Women’s College Hospital Toronto ON CanadaDivision of Dermatology University of Toronto Toronto ON Canada Search for other works by this author on: Oxford Academic Google Scholar Aaron M. Drucker Aaron M. Drucker Women’s College Research Institute Women’s College Hospital Toronto ON CanadaDivision of Dermatology University of Toronto Toronto ON Canada Correspondence: Aaron M. Drucker. Email: aaron.drucker@wchospital.ca https://orcid.org/0000-0002-7388-9475 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 187, Issue 1, 1 July 2022, Pages 127–129, https://doi.org/10.1111/bjd.21025 Published: 01 July 2022